Overview of the main outcomes in breast-cancer prevention trials

J. Cuzick; T. Powles; U. Veronesi; J. Forbes; R. Edwards; S. Ashley; P. Boyle

doi:10.1016/S0140-6736(03)12342-2

Overview of the main outcomes in breast-cancer prevention trials

J. Cuzick, T. Powles, U. Veronesi, J. Forbes, R. Edwards, S. Ashley, P. Boyle

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Early findings on the use of tamoxifen or raloxifene as prophylaxis against breast cancer have been mixed; we update available data and overview the combined results. Methods: All five randomised prevention trials comparing tamoxifen or raloxifene with placebo were included. Relevant data on contralateral breast tumours and side-effects were included from an overview of adjuvant trials of tamoxifen versus control. Findings: The tamoxifen prevention trials showed a 38% (95% Cl 28-46; p

Original language	English
Pages (from-to)	296-300
Number of pages	5
Journal	Lancet
Volume	361
Issue number	9354
DOIs	https://doi.org/10.1016/S0140-6736(03)12342-2
Publication status	Published - Jan 25 2003

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(03)12342-2

Cite this

@article{f17b6f61405740d8ac0a9917f083740d,

title = "Overview of the main outcomes in breast-cancer prevention trials",

abstract = "Background: Early findings on the use of tamoxifen or raloxifene as prophylaxis against breast cancer have been mixed; we update available data and overview the combined results. Methods: All five randomised prevention trials comparing tamoxifen or raloxifene with placebo were included. Relevant data on contralateral breast tumours and side-effects were included from an overview of adjuvant trials of tamoxifen versus control. Findings: The tamoxifen prevention trials showed a 38% (95% Cl 28-46; p",

author = "J. Cuzick and T. Powles and U. Veronesi and J. Forbes and R. Edwards and S. Ashley and P. Boyle",

year = "2003",

month = jan,

day = "25",

doi = "10.1016/S0140-6736(03)12342-2",

language = "English",

volume = "361",

pages = "296--300",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Lancet Publishing Group",

number = "9354",

}

TY - JOUR

T1 - Overview of the main outcomes in breast-cancer prevention trials

AU - Cuzick, J.

AU - Powles, T.

AU - Veronesi, U.

AU - Forbes, J.

AU - Edwards, R.

AU - Ashley, S.

AU - Boyle, P.

PY - 2003/1/25

Y1 - 2003/1/25

N2 - Background: Early findings on the use of tamoxifen or raloxifene as prophylaxis against breast cancer have been mixed; we update available data and overview the combined results. Methods: All five randomised prevention trials comparing tamoxifen or raloxifene with placebo were included. Relevant data on contralateral breast tumours and side-effects were included from an overview of adjuvant trials of tamoxifen versus control. Findings: The tamoxifen prevention trials showed a 38% (95% Cl 28-46; p

AB - Background: Early findings on the use of tamoxifen or raloxifene as prophylaxis against breast cancer have been mixed; we update available data and overview the combined results. Methods: All five randomised prevention trials comparing tamoxifen or raloxifene with placebo were included. Relevant data on contralateral breast tumours and side-effects were included from an overview of adjuvant trials of tamoxifen versus control. Findings: The tamoxifen prevention trials showed a 38% (95% Cl 28-46; p

UR - http://www.scopus.com/inward/record.url?scp=0037464769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037464769&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(03)12342-2

DO - 10.1016/S0140-6736(03)12342-2

M3 - Article

C2 - 12559863

AN - SCOPUS:0037464769

VL - 361

SP - 296

EP - 300

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9354

ER -

Overview of the main outcomes in breast-cancer prevention trials

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this